Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors.
about
Intravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeAseptic meningitis after treatment with amoxicillinImmune thrombocytopenic purpura - current management practices.Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.Prevention of fetal death in the antiphospholipid antibody syndrome.Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Intravenous immunoglobulin in neurological disease: a specialist review.Review of Systemic Immunosuppression for Autoimmune UveitisUtility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications.Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki diseaseIntravenous immune globulins: an update for clinicians.Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event.Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association?A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Intravenous immunoglobulin-associated cranial pachymeningitis.Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.Safety of IGIV therapy and infusion-related adverse events.Immunoglobulin replacement therapy in children.The use of i.v. IG therapy in dermatology.Inpatient management of guillain-barré syndrome.Current treatments of chronic immune-mediated demyelinating polyneuropathies.Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.Immunotherapy of multifocal motor neuropathy.Respiratory syncytial virus prevention and therapy: past, present, and future.Road to remission: a comprehensive review of therapy in uveitis.Immune mechanisms in epileptogenesis.Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.Intravenous immunoglobulin in the treatment of neurologic disorders.
P2860
Q24193522-7CB088F8-5249-4494-ACC7-1EB815ECBDC8Q24202100-BA380B50-94FE-479B-8117-65363A3CA9E4Q24234992-10B0187D-EE49-4B9C-8B75-86A117380EA1Q24244575-48282C3E-CD0D-45DE-B96D-3C6D71F85032Q24247429-D897120B-E3B2-4E80-9F09-4961630B3145Q28343361-C28EBA14-D9BD-438B-9687-B4798EA3C6B7Q33363927-1FE8FE93-D4B9-4497-9022-84DFDD260BFFQ33385549-EA84870D-344C-4757-BECE-8E7A44944446Q33399594-D58D833E-DA0C-4734-8AFD-A46EA9810651Q33497596-FB5F5B25-86E8-4DA6-B580-07378A2A9B6BQ33748109-97639EFA-C5EE-4C01-97DF-15C86F44C002Q34257903-3EC57386-62E8-4083-8DA5-589EC319735BQ34574581-5CB4D1DF-8541-4001-9662-62C4B81E2F23Q34627012-8E93B054-FF0B-4908-B978-4E9882D4E503Q35142598-9B6FEFB6-8914-4CE1-BE97-94674DC5719DQ35292610-89EFD502-9D83-415F-8008-BE384ECFBFEFQ35542385-475F5E92-9BB6-44B6-A44A-6E1947A1D4B0Q36043289-E5E09BC5-1627-4A24-BAFD-542BCE864A13Q36067900-A65111B1-4040-4F3B-AE6F-D28FFFB9AB0EQ36072369-0EC8ED7C-F94C-4392-B62E-704E59FC8634Q36153615-781DAA72-94D7-4586-B153-626F88214297Q36484438-3143B46F-48DE-41D6-8E2F-3BC46370A04FQ36553867-28057099-A03C-4844-BF36-2D6CD5E325CEQ36602771-0C8FB2B4-7FC9-4566-A475-428DC33171D4Q36602804-5A44ED0A-D723-4FE6-A315-06D9379AB11EQ36794149-96AAF3D4-7E7C-4AF1-A002-7F17370B9DA0Q36960970-1C7ED233-42C8-4870-98F4-600AB3B3E010Q36979273-D6175FDA-3477-4FEC-99AE-D3C468B84F3BQ36986054-46605D9F-66FB-4E0C-8FC5-99099B0B326BQ37052679-DE6B475D-8831-4CE7-9A17-BAD5AAE15FC2Q37419250-8BD02CEC-BAFA-4A7D-B276-FCDBB0DE83A6Q37771929-13104F76-70FD-406C-9A34-AC381DEB7CD7Q37791323-AD358B36-D7C0-4FE1-8540-BB54129D44ECQ37836898-D3192B71-6EAB-45AF-A221-2C583EDAB104Q37857806-08FFC7FB-0D68-4370-968A-1A0BF792F82AQ37936459-C02A1709-66B5-49F0-845A-C0268D07653BQ38165168-25A4AC3C-F656-4FB3-8534-0857C3C96E11Q38203801-0F8AAA36-D3F1-4EA5-99E9-FFD12D8B2C86Q38308436-D221D0A9-16DE-4218-80CA-76A08EB727C9Q38495457-45E6E7CF-CCCA-4F38-A36C-A69450F472AC
P2860
Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Aseptic meningitis associated ...... y: frequency and risk factors.
@en
type
label
Aseptic meningitis associated ...... y: frequency and risk factors.
@en
prefLabel
Aseptic meningitis associated ...... y: frequency and risk factors.
@en
P2093
P1476
Aseptic meningitis associated ...... y: frequency and risk factors.
@en
P2093
P304
P356
10.7326/0003-4819-121-4-199408150-00004
P407
P577
1994-08-01T00:00:00Z